Selected research
Industry Research
Dolutegravir Sodium Industry Research Report 2026
Market perspective
The global Dolutegravir Sodium market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Dolutegravir Sodium is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Dolutegravir Sodium is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Dolutegravir Sodium is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Dolutegravir Sodium include Mylan, ViiV Healthcare UK, Ranbaxy Pharmaceuticals, LAURUS Labs, Emcure Pharmaceuticals, Cipla, Aurobindo Pharma and Adcock Ingram Limited, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Dolutegravir Sodium market in terms of revenue (US$ million) and, where applicable, sales volume (k pcs), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/k pcs) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Dolutegravir Sodium Market by Company
Mylan
ViiV Healthcare UK
Ranbaxy Pharmaceuticals
LAURUS Labs
Emcure Pharmaceuticals
Cipla
Aurobindo Pharma
Adcock Ingram Limited
Dolutegravir Sodium Segment by Type
Bottled Packaging
Film Coated Packaging
Dolutegravir Sodium Segment by Application
AIDS Adult Patients
AIDS Children over 12 Years Old
Dolutegravir Sodium Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Dolutegravir Sodium market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Dolutegravir Sodium and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Dolutegravir Sodium.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Dolutegravir Sodium manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Dolutegravir Sodium by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Dolutegravir Sodium in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bottled Packaging
- Film Coated Packaging
Applications
- AIDS Adult Patients
- AIDS Children over 12 Years Old
Companies covered
- Mylan
- ViiV Healthcare UK
- Ranbaxy Pharmaceuticals
- LAURUS Labs
- Emcure Pharmaceuticals
- Cipla
- Aurobindo Pharma
- Adcock Ingram Limited
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Dolutegravir Sodium Market Size (2021-2032)
- 2.2.2 Global Dolutegravir Sodium Sales (2021-2032)
- 2.2.3 Global Dolutegravir Sodium Market Average Price (2021-2032)
- 2.3 Dolutegravir Sodium by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Bottled Packaging
- 2.3.3 Film Coated Packaging
- 2.4 Dolutegravir Sodium by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 AIDS Adult Patients
- 2.4.3 AIDS Children over 12 Years Old
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Dolutegravir Sodium Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Dolutegravir Sodium Sales (k pcs) of Manufacturers (2021-2026)
- 3.3 Global Dolutegravir Sodium Revenue of Manufacturers (2021-2026)
- 3.4 Global Dolutegravir Sodium Average Price by Manufacturers (2021-2026)
- 3.5 Global Dolutegravir Sodium Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Dolutegravir Sodium, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Dolutegravir Sodium, Product Type & Application
- 3.8 Global Manufacturers of Dolutegravir Sodium, Established Date
- 3.9 Global Dolutegravir Sodium Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Mylan
- 4.1.1 Mylan Company Information
- 4.1.2 Mylan Business Overview
- 4.1.3 Mylan Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Mylan Dolutegravir Sodium Product Portfolio
- 4.1.5 Mylan Recent Developments
- 4.2 ViiV Healthcare UK
- 4.2.1 ViiV Healthcare UK Company Information
- 4.2.2 ViiV Healthcare UK Business Overview
- 4.2.3 ViiV Healthcare UK Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 ViiV Healthcare UK Dolutegravir Sodium Product Portfolio
- 4.2.5 ViiV Healthcare UK Recent Developments
- 4.3 Ranbaxy Pharmaceuticals
- 4.3.1 Ranbaxy Pharmaceuticals Company Information
- 4.3.2 Ranbaxy Pharmaceuticals Business Overview
- 4.3.3 Ranbaxy Pharmaceuticals Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Ranbaxy Pharmaceuticals Dolutegravir Sodium Product Portfolio
- 4.3.5 Ranbaxy Pharmaceuticals Recent Developments
- 4.4 LAURUS Labs
- 4.4.1 LAURUS Labs Company Information
- 4.4.2 LAURUS Labs Business Overview
- 4.4.3 LAURUS Labs Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 LAURUS Labs Dolutegravir Sodium Product Portfolio
- 4.4.5 LAURUS Labs Recent Developments
- 4.5 Emcure Pharmaceuticals
- 4.5.1 Emcure Pharmaceuticals Company Information
- 4.5.2 Emcure Pharmaceuticals Business Overview
- 4.5.3 Emcure Pharmaceuticals Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Emcure Pharmaceuticals Dolutegravir Sodium Product Portfolio
- 4.5.5 Emcure Pharmaceuticals Recent Developments
- 4.6 Cipla
- 4.6.1 Cipla Company Information
- 4.6.2 Cipla Business Overview
- 4.6.3 Cipla Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Cipla Dolutegravir Sodium Product Portfolio
- 4.6.5 Cipla Recent Developments
- 4.7 Aurobindo Pharma
- 4.7.1 Aurobindo Pharma Company Information
- 4.7.2 Aurobindo Pharma Business Overview
- 4.7.3 Aurobindo Pharma Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Aurobindo Pharma Dolutegravir Sodium Product Portfolio
- 4.7.5 Aurobindo Pharma Recent Developments
- 4.8 Adcock Ingram Limited
- 4.8.1 Adcock Ingram Limited Company Information
- 4.8.2 Adcock Ingram Limited Business Overview
- 4.8.3 Adcock Ingram Limited Dolutegravir Sodium Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Adcock Ingram Limited Dolutegravir Sodium Product Portfolio
- 4.8.5 Adcock Ingram Limited Recent Developments
5 Global Dolutegravir Sodium Market Scenario by Region
- 5.1 Global Dolutegravir Sodium Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Dolutegravir Sodium Sales by Region: 2021-2032
- 5.2.1 Global Dolutegravir Sodium Sales by Region: 2021-2026
- 5.2.2 Global Dolutegravir Sodium Sales by Region: 2027-2032
- 5.3 Global Dolutegravir Sodium Revenue by Region: 2021-2032
- 5.3.1 Global Dolutegravir Sodium Revenue by Region: 2021-2026
- 5.3.2 Global Dolutegravir Sodium Revenue by Region: 2027-2032
- 5.4 North America Dolutegravir Sodium Market Facts & Figures by Country
- 5.4.1 North America Dolutegravir Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Dolutegravir Sodium Sales by Country (2021-2032)
- 5.4.3 North America Dolutegravir Sodium Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.4.6 Mexico
- 5.5 Europe Dolutegravir Sodium Market Facts & Figures by Country
- 5.5.1 Europe Dolutegravir Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Dolutegravir Sodium Sales by Country (2021-2032)
- 5.5.3 Europe Dolutegravir Sodium Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Russia
- 5.5.9 Spain
- 5.5.10 Netherlands
- 5.5.11 Switzerland
- 5.5.12 Sweden
- 5.5.13 Poland
- 5.6 Asia Pacific Dolutegravir Sodium Market Facts & Figures by Country
- 5.6.1 Asia Pacific Dolutegravir Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Dolutegravir Sodium Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Dolutegravir Sodium Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Dolutegravir Sodium Market Facts & Figures by Country
- 5.7.1 South America Dolutegravir Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Dolutegravir Sodium Sales by Country (2021-2032)
- 5.7.3 South America Dolutegravir Sodium Revenue by Country (2021-2032)
- 5.7.4 Brazil
- 5.7.5 Argentina
- 5.7.6 Chile
- 5.7.7 Colombia
- 5.8 Middle East and Africa Dolutegravir Sodium Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Dolutegravir Sodium Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Dolutegravir Sodium Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Dolutegravir Sodium Revenue by Country (2021-2032)
- 5.8.4 Egypt
- 5.8.5 South Africa
- 5.8.6 Israel
- 5.8.7 Türkiye
- 5.8.8 GCC Countries
6 Segment by Type
- 6.1 Global Dolutegravir Sodium Sales by Type (2021-2032)
- 6.1.1 Global Dolutegravir Sodium Sales by Type (2021-2032) & (k pcs)
- 6.1.2 Global Dolutegravir Sodium Sales Market Share by Type (2021-2032)
- 6.2 Global Dolutegravir Sodium Revenue by Type (2021-2032)
- 6.2.1 Global Dolutegravir Sodium Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Dolutegravir Sodium Revenue Market Share by Type (2021-2032)
- 6.3 Global Dolutegravir Sodium Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Dolutegravir Sodium Sales by Application (2021-2032)
- 7.1.1 Global Dolutegravir Sodium Sales by Application (2021-2032) & (k pcs)
- 7.1.2 Global Dolutegravir Sodium Sales Market Share by Application (2021-2032)
- 7.2 Global Dolutegravir Sodium Revenue by Application (2021-2032)
- 7.2.1 Global Dolutegravir Sodium Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Dolutegravir Sodium Revenue Market Share by Application (2021-2032)
- 7.3 Global Dolutegravir Sodium Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Dolutegravir Sodium Value Chain Analysis
- 8.1.1 Dolutegravir Sodium Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Dolutegravir Sodium Production Mode & Process
- 8.2 Dolutegravir Sodium Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Dolutegravir Sodium Distributors
- 8.2.3 Dolutegravir Sodium Customers
9 Global Dolutegravir Sodium Analyzing Market Dynamics
- 9.1 Dolutegravir Sodium Industry Trends
- 9.2 Dolutegravir Sodium Industry Drivers
- 9.3 Dolutegravir Sodium Industry Opportunities and Challenges
- 9.4 Dolutegravir Sodium Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst